Cosmos Health (NASDAQ:COSM) CEO Grigorios Siokas Buys 51,315 Shares

Cosmos Health Inc. (NASDAQ:COSM) CEO Grigorios Siokas acquired 51,315 shares of the company’s stock in a transaction dated Thursday, November 20th. The stock was bought at an average cost of $0.62 per share, for a total transaction of $31,815.30. Following the completion of the transaction, the chief executive officer directly owned 6,271,813 shares of the company’s stock, valued at approximately $3,888,524.06. This trade represents a 0.82% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Grigorios Siokas also recently made the following trade(s):

• On Wednesday, November 19th, Grigorios Siokas bought 61,614 shares of Cosmos Health stock. The shares were bought at an average cost of $0.65 per share, with a total value of $40,049.10.

Cosmos Health Stock Performance

COSM traded up $0.05 on Friday, reaching $0.68. The company had a trading volume of 167,846 shares, compared to its average volume of 430,412. The company’s fifty day moving average is $0.93 and its 200 day moving average is $0.71. The company has a debt-to-equity ratio of 0.25, a quick ratio of 0.82 and a current ratio of 0.99. The stock has a market cap of $23.66 million, a P/E ratio of -0.90 and a beta of 5.32. Cosmos Health Inc. has a fifty-two week low of $0.28 and a fifty-two week high of $1.32.

Cosmos Health (NASDAQ:COSM) last issued its quarterly earnings data on Friday, November 14th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.16). The firm had revenue of $17.11 million for the quarter, compared to the consensus estimate of $16.40 million. Cosmos Health had a negative return on equity of 33.19% and a negative net margin of 31.01%. As a group, analysts predict that Cosmos Health Inc. will post -0.78 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Cosmos Health in a research note on Wednesday, October 8th. Wall Street Zen upgraded shares of Cosmos Health to a “hold” rating in a research report on Saturday, September 20th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Cosmos Health currently has a consensus rating of “Sell”.

Hedge Funds Weigh In On Cosmos Health

A hedge fund recently raised its stake in Cosmos Health stock. Citadel Advisors LLC lifted its position in shares of Cosmos Health Inc. (NASDAQ:COSM) by 133.1% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 225,507 shares of the company’s stock after acquiring an additional 128,776 shares during the period. Citadel Advisors LLC owned approximately 0.65% of Cosmos Health worth $250,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 12.61% of the company’s stock.

About Cosmos Health

Cosmos Health Inc manufactures, develops, and trades branded nutraceutical products in Greece, the United Kingdom, Croatia, Bulgaria, Cayman Islands, and Cyprus. It offers medicines, OTC medicines, nutraceutical products, vitamins, minerals and dietary, health care products, medical devices, baby products, and others under the Sky Premium Life and Mediterranation brand names.